Spartalizumab
CAS: 1935694-88-4
Rif. TM-T77075
1mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione |
Informazioni sul prodotto
- PDR001
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that selectively binds to PD-1 at low concentrations and shows high activity. Spartalizumab blocks the interaction with PD-L1 and PD-L2, and can be used to study undifferentiated thyroid cancer (ATC).